Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 12/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772005 | 0.81 | CYP2A6 (0.88) | CYP2A6ALDH1A1CYP3A4CYP1A2KDM4E | |
| SCHEMBL1742451 | 0.81 | CYP2A6 (1.00) | CYP2A6ALDH1A1CYP3A4CYP1A2KDM4E | |
| SCHEMBL120088 | 0.81 | CYP2A6 (1.00) | CYP2A6ALDH1A1CYP3A4CYP1A2KDM4E | |
| SCHEMBL30473120 | 0.81 | CYP2A6 (1.00) | CYP2A6ALDH1A1CYP3A4CYP1A2KDM4E | |
| SCHEMBL29419014 | 0.81 | CYP2A6 (1.00) | CYP2A6ALDH1A1CYP3A4CYP1A2KDM4E | |
| SCHEMBL16352428 | 0.78 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP3A4CYP1A2KDM4E | |
| SCHEMBL25523070 | 0.78 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP3A4CYP1A2KDM4E | |
| SCHEMBL10918242 | 0.78 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP3A4CYP1A2KDM4E | |
| SCHEMBL27812368 | 0.78 | CYP2A6 (0.94) | CYP2A6ALDH1A1CYP3A4CYP1A2KDM4E | |
| Hydrochloric Acid SCHEMBL4831090 | 0.78 | CYP2A6 (0.94) | CYP2A6ALDH1A1CYP3A4CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2024-09-05 | — | — | US | disclosed |
| CN-112689507-B | Amino acid compounds having unbranched linkers and methods of use thereof | 普利安特治疗公司 | 2024-07-30 | — | — | CN | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220289743-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-09-15 | — | — | US | disclosed |
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3813818-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112689507-A | Amino acid compounds having unbranched linkers and methods of use thereof | 普利安特治疗公司 | 2021-04-20 | — | — | CN | disclosed |
| US-20200123151-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-23 | — | — | US | disclosed |
| EP-2613775-B1 | N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-8716285-B2 | N-hydroxy-benzamids for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2613775-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| CN-103200936-A | Novel N-hydroxybenzamide compounds for the treatment of cancer | HOFFMANN LA ROCHE | 2013-07-10 | — | — | CN | disclosed |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012031993-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | CYP2A6 3851/4885ALDH1A1 2694/4885CYP3A4 4816/4885 |
| US-20200123151-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | CYP2A6 3851/4885ALDH1A1 2694/4885CYP3A4 4816/4885 |
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | CYP2A6 3851/4885ALDH1A1 2694/4885CYP3A4 4816/4885 |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | HNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRAS | CYP2A6 1809/4885ALDH1A1 158/4885CYP3A4 332/4885 |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | CYP2A6 3851/4885ALDH1A1 2694/4885CYP3A4 4816/4885 |
| US-20220289743-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | CYP2A6 3851/4885ALDH1A1 2694/4885CYP3A4 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.